RxDoctor Payments Data

Leena Sharan, MD

Cardiovascular Disease · Plano, TXNPI 1326006685

Payments from drug & device makers

$71,415in general payments, 2019–2025

Across 818 payments — averaging $87.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54K
  • Medtronic$3K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Amgen$1K
  • Abbott$1K
  • plus $9K from 47 others

What the payments were for

  • Consulting fees$1170%
  • Speaking & faculty fees$50,25070%
  • Travel & lodging$1,4892%
  • Food & beverage$19,54027%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,415 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$864,078
Medicare patients
1,056
Services billed
6,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$484,251
XareltoRivaroxaban188$223,949
EntrestoSacubitril/Valsartan76$101,910
Repatha SureclickEvolocumab47$35,994
BrilintaTicagrelor30$29,465
Valsartan199$7,553
Metoprolol Succinate593$6,840
Clonidine37$5,900
Midodrine Hcl19$3,443
Ranolazine ErRanolazine29$2,808
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$2,512
Atorvastatin Calcium334$2,441
Rosuvastatin Calcium239$2,312
Flecainide Acetate46$2,259
Nifedipine ErNifedipine61$2,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,027$484,251405 claims
Johnson & JohnsonXarelto$1,751$223,949188 claims
NovartisEntresto$1,365$101,91076 claims
AstraZenecaBrilinta$390$29,46530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →